<DOC>
	<DOCNO>NCT02052310</DOCNO>
	<brief_summary>The purpose study determine whether FG-4592 ( roxadustat ) safe effective treatment anemia patient begin dialysis treatment end stage renal disease .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment Anemia ESRD Newly Initiated Dialysis Patients</brief_title>
	<detailed_description>There screen period 6 week , treatment period minimum 52 week maximum approximately 3 year last patient randomize , post-treatment follow-up period 4 week . A total 750 patient randomize 1:1 ratio receive either open-label FG-4592 Active Control ( Epoetin alfa ) .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Age â‰¥18 year . 2 . Receiving hemodialysis peritoneal dialysis endstage renal disease minimum 2 week maximum 4 month , prior study participation . 3 . Study participant permanent dialysis access place . 4 . No iron deficiency . 5 . No folate Vitamin B12 deficiency . 6 . No abnormal liver test . 7 . Body weight 160 kg ( HD : dry weight ) . Note : Blood test conduct determine whether study participant anemia , meet eligibility criterion . 1 . Any erythropoieisisstimulating agent treatment within 12 week prior participate study . 1 . UNITED STATES ONLY Total duration prior effective ESA use must less equal 3 week within precede 12 week time consent obtain . 2 . Intravenous iron within 10 day prior participate study . 3 . Red blood cell transfusion within 8 week prior participate study . 4 . Active infection . 5 . Chronic liver disease ( e.g. , chronic infectious hepatitis , chronic autoimmune liver disease , cirrhosis , fibrosis liver ) . 6 . Congestive heart failure . 7 . Heart attack , stroke , bloodclots within major vessel within 12 week prior participate study . 8 . Uncontrolled high blood pressure within 2 week prior participate study . 9 . Renal ultrasound perform within 12 week prior participate study suspicious renal cancer . 10 . Active cancer . 11 . Positive human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. 12 . Chronic inflammatory disease could cause anemia . 13 . Known untreated damage retina diabetes . 14 . Known history bloodrelated disease cause anemia , bloodrelated cancer . 15 . Known inherited disease thalassemia sickle cell anemia know cause anemia chronic kidney disease . 16 . Known clot disorder iron storage disorder . 17 . Any prior organ transplant ( explanted ) , schedule organ transplantation . 18 . Anticipated surgery expect cause blood loss . 19 . Known gastrointestinal bleeding . 20 . Any prior treatment FG4592 ( roxadustat ) hypoxiainducible factor prolyl hydroxylase inhibitor . 21 . Use ironbinding medication within 4 week prior participate study . 22 . Known allergy erythropoieisisstimulating agent . 23 . Use investigational drug treatment , participation investigational study , presence expect carryover effect investigational treatment , within 4 week prior participate study . 24 . Anticipated use dapsone androgen dose amount chronic use acetaminophen paracetamol &gt; 2.0 g/day study . 25 . History alcohol drug abuse within 2 year prior participate study . 26 . Women become pregnant must use contraception . Men sexual partner become pregnant must use birth control , unless man agree use contraception . 27 . Pregnant breastfeed woman . 28 . Any medical condition , opinion study doctor , may pose safety risk patient , may confound efficacy safety assessment , may interfere study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>Incident-Dialysis</keyword>
	<keyword>Erythropoieitin</keyword>
	<keyword>Erythropoieisis stimulating-agent</keyword>
	<keyword>Roxadustat</keyword>
	<keyword>AZD9941</keyword>
	<keyword>ASP1517</keyword>
</DOC>